Continuing challenges in influenza

Annals of the New York Academy of Sciences

Volumn 1323, Issue 1, 2014, Pages 115-139

  Webster, Robert G ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antigenic changes; Antiviral drugs; H1N1; H5N1; H7N9; Influenza virus; Pandemic; Vaccines; Zoonosis

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; SIALIDASE INHIBITOR; IMMUNOLOGICAL ADJUVANT; VACCINE; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; ANTIGENIC DRIFT; ANTIGENIC SHIFT; ANTIGENICITY; ANTIVIRAL RESISTANCE; ARTICLE; BIOLOGY; DISEASE SEVERITY; DRUG FORMULATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H2N3; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N9; INFLUENZA VIRUS A H9N2; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ANTIGENIC CHANGES; ANTIVIRAL DRUGS; IMMUNOLOGY; INFLUENZA VIRUS; PANDEMIC; REVIEW; SWINE; ZOONOSIS;

ANTIGENIC CHANGES; ANTIVIRAL DRUGS; H1N1; H5N1; H7N9; INFLUENZA VIRUS; PANDEMIC; VACCINES; ZOONOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; SWINE;

EID: 84907954836     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12462     Document Type: Article

References (139)

1. Shaw, M.L. & P. Palese . 2011. "Orthomyxoviradae: the viruses and their replication." In Fields' Virology, 6th ed. D. Knipe & P. Howley, Eds.: 1647-1689. Philadelphia, PA: Lippin Williams & Wilkins.
2. Webster, R.G., W.J. Bean, O.T. Gorman, et al. 1994. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56: 152-179.
3. Jernigan, D.B. & N.J. Cox . 2013. "Human influenza: One Health, One World." In Textbook of Influenza, 2nd ed. R.G. Webster, A.S. Monto, T.J. Braciale & R.A. Lamb, Eds.: 3-19. West Sussex: John Wiley and Sons.
4. Russell, R.J., P.S. Kerry, D.J. Stevens, et al. 2008. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. U. S. A. 105: 17736-17741.
5. Tong, S., X. Zhu, Y. Li, et al. 2013. New world bats harbor diverse influenza A viruses. PLoS Pathog. 9: e1003657.
6. Perdue, M.L. 2008. "Molecular determinants of pathogenicity for avian influenza viruses." In Avian Influenza. D.E. Swayne, Ed.: 23-41. Ames, Iowa: Blackwell Publishing.
7. Klenk, H.D., W. Garten & M. Matrosovich . 2013. "Pathogenesis." In Textbook of Influenza, 2nd ed. R.G. Webster, A.S. Monto, T.J. Braciale & R.A. Lamb, Eds.: 157-171. West Sussex: John Wiley and Sons.
8. CDC. 2002. Surveillance for Influenza-United States, 1997-98, 1998-99, and 1999-00 Seasons. MMWR Surveill. Summ. 51(SS07): 1-10.
9. CDC. 2003. Update: influenza Activity-United States, 2003-04 Season. MMWR Morb. Mortal. Wkly. Rep. 49: 1197-1202.
10. Treanor, J. 2004. Influenza vaccine-outmaneuvering antigenic shift and drift. N. Engl. J. Med. 350: 218-220.
11. Laver, W.G., G.M. Air, R.G. Webster, et al. 1979. Antigenic drift in type A influenza virus: sequence differences in the hemagglutinin of Hong Kong (H3N2) variants selected with monoclonal hybridoma antibodies. Virology 98: 226-237.
12. Wilson, I.A., N.J. Cox . 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Ann. Rev. Immunol. 8: 737-771.
13. World Health Organization (WHO). 2014. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases WHO/CDS/CSR/ISR2000.1. http://www.shimclinic.com/singapore/influenza-vaccine-history. Accessed February 17, 2014
14. Koel, B.F., D.F. Burke, T.M. Bestebroer, et al. 2013. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342: 976-979.
15. Nabel, G.J. & A.S. Fauci . 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16: 1389-1391.
16. Yuan, J., L. Zhang, X. Kan, et al. 2013. Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. Clin. Infect. Dis. 57: 1367-1368.
17. ProMED-mail. Avian Influenza, Human (158): China (Ziangxi) H10N8, Fatal, 2013 Dec 17. cited Feb 17, 2014. http://www.promedmail.org [archive number 20131217.2121718].
18. Simonsen, L., M.J. Clarke, L.B. Schonberger, et al. 1998. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 178: 53-60.
19. Jones, J.C., T. Baranovich, B.M. Marathe, et al. 2013. Risk assessment of H2N2 influenza viruses from the avian reservoir. J. Virol. 88: 1175-1188.
20. Schäfer, J.R., Y. Kawaoka, W.J. Bean, et al. 1993. Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir. Virology 194: 781-788.
21. Ma, W., A.L. Vincent, M.R. Gramer, et al. 2007. Identification of H2N3 influenza A viruses from swine in the United States. Proc. Natl. Acad. Sci. U. S. A. 104: 20949-20954.
22. Van Kerkhove, M.D., S. Riley, M. Lipsitch, et al. 2012. Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". Science 336: 1506[author reply 1506].
23. Wang, Z., A. Zhang, Y. Wan, et al. 2013. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc. Natl. Acad. Sci. U. S. A. 111: 769-774.
24. Imai, M., T. Watanabe, M. Hatta, et al. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428.
25. Herfst, S., E.J. Schrauwen, M. Linster, et al. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541.
26. Zhang, Y., Q. Zhang, H. Kong, et al. 2013. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 340: 1459-1463.
27. Belser, J.A., C.T. Davis, A. Balish, et al. 2013. Pathogenesis, transmissibility, and ocular tropism of a highly pathogenic avian influenza A (H7N3) virus associated with human conjunctivitis. J. Virol. 87: 5746-5754.
28. Koopmans, M., R. Fouchier, B. Wilbrink, et al. 2003. Update on human infections with highly pathogenic avian influenza virus A/H7N7 during an outbreak in poultry in The Netherlands. Euro. Surveill. 7: 2217.
29. Mo, I.P., C.S. Song, K.S. Kim, et al. 1997. An occurrence of non-highly pathogenic avian influenza in Korea. In Proceedings of the Fourth International Symposium on Avian Influenza. D. Swayne & R. Slemons, Eds.: 379-383. Tallahassee: United States Animal Health Association, Rose Printing Company.
30. Guo, Y.J., S. Krauss, D.A. Senne, et al. 2000. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology 267: 279-288.
31. Alexander, D.J. 2003. Report on avian influenza in the Eastern Hemisphere during 1997-2002. Avian Dis. 47(3 Suppl): 792-797.
32. Fusaro, A., I. Monne, A. Salviato, et al. 2011. Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. J. Virol. 85: 8413-8421.
33. Lin, Y.P., M. Shaw, V. Gregory, et al. 2000. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc. Natl. Acad. Sci. U. S. A. 97: 9654-9658.
34. Matrosovich, M.N., S. Krauss, R.G. Webster . 2001. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology 281: 156-162.
35. Shanmuganatham, K., M.M. Feeroz, L. Jones-Engel, et al. 2013. Antigenic and molecular characterization of avian influenza A(H9N2) viruses, Bangladesh. Emerg. Infect. Dis. 19: 1393-1402.
36. Butt, K.M., G.J. Smith, H. Chen, et al. 2005. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J. Clin. Microbiol. 43: 5760-5767.
37. Yu, H., Y.J. Zhou, G.X. Li, et al. 2011. Genetic diversity of H9N2 influenza viruses from pigs in China: a potential threat to human health? Vet. Microbiol. 149: 254-261.
38. Gao, R., B. Cao, Y. Hu, et al. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368: 1888-1897.
39. Leung, Y.H., E.H. Lau, L.J. Zhang, et al. 2012. Avian influenza and ban on overnight poultry storage in live poultry markets, Hong Kong. Emerg. Infect. Dis. 18: 1339-1341.
40. Xu, R., D.C. Ekiert, J.C. Krause, et al. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328: 357-360.
41. Domínguez-Cherit, G., S.E. Lapinsky, A.E. Macias, et al. 2009. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302: 1880-1887.
42. Scholtissek, C. 1990/1991. Pigs as "mixing vessels" for the creation of new pandemic influenza A viruses. Med. Principles Pract. 2: 65-71.
43. Smith, G.J., D. Vijaykrishna, J. Bahl, et al. 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459: 1122-1125.
44. Ducatez, M.F., B. Hause, E. Stigger-Rosser, et al. 2011. Multiple reassortment between pandemic (H1N1) 2009 and endemic influenza viruses in pigs, United States. Emerg. Infect. Dis. 17: 1624-1629.
45. Jhung, M.A., S. Epperson, M. Biggerstaff, et al. 2013. Outbreak of variant influenza A(H3N2) virus in the United States. Clin. Infect. Dis. 57: 1703-1712.
46. nd ed. R.G. Webster, A.S. Monto, T.J. Braciale & R.A. Lamb, Eds.: 20-33. West Sussex: John Wiley and Sons.
47. Fiore, A.E., T.M. Uyeki, K. Broder, et al. 2010. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm. Rep. 59: 1-62.
48. CDC. Summary Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-(ACIP)-United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm. Accessed April 23, 2014.
49. Reed, C., M.I. Meltzer, L. Finelli, et al. 2012. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30: 1993-1998.
50. Okuno, Y., Y. Isegawa, F. Sasao, et al. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67: 2552-2558.
51. Throsby, M., E.van denBrink, M. Jongeneelen, et al. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
52. Ekiert, D.C., G. Bhabha, M. A. Elsliger, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
53. Sui, J., W.C. Hwang, S. Perez, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16: 265-273.
54. Ekiert, D.C. & I.A. Wilson . 2012. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2: 134-141
55. Ekiert, D.C., R.H. Friesen, G. Bhabha, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
56. Friensen, R.H., P.S. Lee, E.J. Stoop, et al. 2013. A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. U. S. A. 111: 445-450.
57. Yoshida, R., M. Igarashi, H. Ozaki, et al. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5: e1000350.
58. Corti, D., J. Voss, S.J. Gamblin, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
59. Dreyfus, C., N.S. Laursen, T. Kwaks, et al. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
60. Clinical Trials.gov 2010. 2014. http://www.ClinicalTrials.gov. http://clinicaltrials.gov. Accessed March 5, 2014.
61. Xu, R., J.C. Krause, R. McBride, et al. 2013. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat. Struct. Mol. Biol. 20: 363-370.
62. Wei, C.J., J.C. Boyington, P.M. McTamney, et al. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
63. Wei, C.J., H.M. Yassine, P.M. McTamney, et al. 2012. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 4: 147ra114.
64. Bommakanti, G., M.P. Citron, R.W. Hepler, et al. 2010. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. U. S. A. 107: 13701-13706.
65. Steel, J., A.C. Lowen, T.T. Wang, et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018-10.
66. Wang, T.T., G.S. Tan, R. Hai, et al. 2010. Vaccination with asynthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 107: 18979-18984.
67. Khurana, S., C.L. Loving, J. Manischewitz, et al. 2013. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci. Transl. Med. 5: 200ra114.
68. Crowe, J.E., Jr. 2013. Universal flu vaccines: primum non nocere. Sci. Transl. Med. 28: 200fs34.
69. O'Hagan, D.T., T. Tsai, and S. Reed . 2011. "Emulsion-based adjuvants for improved influenza vaccines." In Influenza Vaccines for the Future, 2nd ed. R. Rappuoli & G. Del Giudice, Eds.: 327-357. Basel: Springer.
70. Freund, J., J. Casals, and E.P. Hosmer . 1937. Sensitization and antibody formation after injection of turbecle bacilli and paraffin oil. Proc. Exp. Biol. Med. 37: 509-513.
71. Stuart-Harris, C.H. 1969. Adjuvant influenza vaccines. Bull. World Health Organ. 41: 617-621.
72. Treanor, J.J., J.D. Campbell, K.M. Zangwill, et al. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354: 1343-51.
73. Levie, K., I. Leroux-Roels, K. Hoppenbrouwers, et al. 2008. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198: 642-649.
74. Luca, G., J. Haba-Rubio, Y. Dauvilliers, et al. 2013. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J. Sleep. Res. 22: 482-495.
75. + T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci. Transl. Med. 5: 216ra176.
76. Davies, W.L., R.R. Grunert, R.F. Haff, et al. 1964. Antiviral activity of 1-adamantanamine (Amantadine). Science 144: 862-863.
77. Air, G.M. 2012. Influenza neuraminidase. Influenza Other Respir. Viruses 6: 245-256.
78. Aoki, F.Y., M.D. Macleod, P. Paggiaro, et al. 2003. Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51: 123-129.
79. Wathen, M.W., M. Barro, & R.A. Bright . 2013. Antivirals in seasonal and pandemic influenza-future perspectives. Influenza and Other Respir. Viruses 7: 76-80.
80. Babu, Y.S., P. Chand, S. Bantia, et al. 2000. BCX-1812-a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43: 3482-3486.
81. Bantia, S., C.S. Arnold, C.D. Parker, et al. 2006. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69: 39-45.
82. Ikematsu, H. & N. Kawai . 2011. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev. Anti. Infect. Ther. 9: 851-857.
83. Gubareva, L.V. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103: 199-203.
84. Collins, P.J., L.F. Haire, Y.P. Lin, et al. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-1261.
85. Samson, M., A. Pizzorno, Y. Abed, et al. 2013. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 98: 174-185.
86. Zürcher, T., P.J. Yates, J. Daly, et al. 2006. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J. Antimicrob. Chemother. 58: 723-732.
87. Thorlund, K., T. Awad, G. Boivin, et al. 2011. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect. Dis. 11: 134.
88. Monto, A.S., J.L. McKimm-Breschkin, C. Macken, et al. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50: 2395-2402.
89. Ward, P., I. Small, J. Smith, et al. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl 1): i5-i21.
90. Dharan, N.J., L.V. Gubareva, J.J. Meyer, et al. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301: 1034-1041.
91. Hauge, S.H., S. Dudman, K. Borgen, et al. 2009. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 15: 155-162.
92. Meijer, A., A. Lackenby, O. Hungnes, et al. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe 2007-08 season. Emerg. Infect. Dis. 15: 552-560.
93. Collins, P.J., L.F. Haire, Y.P. Lin, et al. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27: 6317-6323.
94. Rameix-Welti, M.A., S. Munier, S. Le Gal, et al. 2011. Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antivir. Ther. 16: 597-603.
95. Bloom, J.D., L.I. Gong & D. Baltimore . 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
96. Renaud, C., J. Kuypers & J.A. Englund . 2011. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J. Clin. Virol. 52: 70-78.
97. Storms, A.D., L.V. Gubareva, S. Su, et al. 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg. Infect. Dis. 18: 308-311.
98. Lackenby, A., J. Moran Gilad, R. Pebody, et al. 2011. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro. Surveill. 16: 19784.
99. Hurt, A.C., K. Hardie, N.J. Wilson, et al. 2011. Community transmission of oseltamivir resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365: 2541-2542.
100. Mai, L.Q., H.F. Wertheim, T.N. Duong, et al. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 362: 86-87.
101. Houng, H.S., J. Garner, Y. Zhou, et al. 2012. Emergent 2009 influenza A(H1N1) viruses containing HA D222N mutation associated with severe clinical outcomes in the Americas. J. Clin. Virol. 53: 12-15.
102. World Health Organization. 2010. WHO guidelines for pharmacological management of pandemic influenza A/H1N1 2009 and other influenza viruses 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf. Accessed February 17, 2014.
103. Malakhov, M.P., L.M. Aschenbrenner, D.F. Smee, et al. 2006. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50: 1470-1479.
104. Nicholls, J.M., R.B. Moss & S.M. Haslam . 2013. The use of sialidase therapy for respiratory viral infections. Antiviral Res. 98: 401-409.
105. Moss, R.B., C. Hansen, R.L. Sanders, et al. 2012. A Phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J. Infect. Dis. 206: 1844-1851.
106. Furuta, Y., K. Takahashi, M. Kuno-Maekawa, et al. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49: 981-986.
107. Sleeman, K., V.P. Mishin, V.M. Deyde, et al. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54: 2517-2524.
108. Kiso, M., K. Takahashi, Y. Sakai-Tagawa, et al. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U. S. A. 107: 882-887.
109. Fox, L. & L.D. Saravolatz . 2006. Nitazoxanide a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40: 1173-1180.
110. Korba, B.E., A.B. Montero, K. Farrar, et al. 2008. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir. Res. 77: 56-63.
111. Stachulski, A.V., C. Pidathala, E.C. Row, et al. 2011. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. J. Med. Chem. 54: 8670-8680.
112. Rossignol, J.F., S. La Frazia, L. Chiappa, et al. 2009. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284: 29798-29808.
113. Edinger, T.O., M.O. Pohl & S. Stertz . 2014. Entry of influenza A virus: host factors and antiviral targets. J. Gen. Virol. 95(Pt 2): 263-277.
114. Ochiai, H., S. Sakai, T. Hirabayashi, et al. 1995. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza and B viruses in MDCK cells. Antiviral Res. 27: 425-430.
115. Wang, J., C. Ma, H. Jo, et al. 2013. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug resistant mutant, S31N, of the M2 proton channel from influenza A virus. J. Med. Chem. 56: 2804-2812.
116. Planz, O. 2013. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Res. 98: 457-468.
117. de Jong, M.D., C.P. Simmons, T.T. Thanh, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12: 1203-1207.
118. Kobasa, D., S.M. Jones, K. Shinya, et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
119. WHO Writing Committee. 2010. Clinical aspects of pandemic influenza A (H1N1) 2009. N. Engl. J. Med. 362: 1708-1719.
120. Darwish, I., S. Mubareka & W.C. Liles . 2011. Immunomodulatory therapy for severe influenza. Expert Rev. Anti Infect. Ther. 9: 807-822.
121. Mao, H., W. Tu, G. Qin, et al. 2009. Influenza virus directly infects human natural killer cells and induces cell apoptosis. J. Virol. 83: 9215-9222.
122. Mao, H., W. Tu, Y. Liu, et al. 2010. Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J. Virol. 84: 4148-4157.
123. Carding, S.R. & P.J. Egan . 2002. Gammadelta T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2: 336-345.
124. Bonneville, M., R.L. O'Brien & W.K. Born . 2010. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10: 467-478.
125. Tu, W., J. Zheng, Y. Liu, et al. 2011. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J. Exp. Med. 208: 1511-1522.
126. Hung, I.F., K.K. To, C.K. Lee, et al. 2011. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52: 510-519.
127. Hung, I.F., K.K. To, C.K. Lee, et al. 2013. Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 44: 464-473.
128. Govorkova, E.A. & R.G. Webster . 2010. Combination chemotherapy for influenza. Viruses 2: 1510-1529.
129. Hoopes, J.D., E.M. Driebe, E. Kelley, et al. 2011. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 6: e29778.
130. Ilyushina, N.A., E. Hoffmann, R. Salomon, et al. 2007. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12: 363-370.
131. Ilyushina N.A., A. Hay, N. Yilmaz, et al. 2008. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 52: 3889-3897.
132. Nguyen, J.T., D.F. Smee, D.L. Barnard, et al. 2012. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 7: e31006.
133. Smee, D.F., B.L. Hurst, M.H. Wong, et al. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53: 2120-2128.
134. Kim, W.Y., S.G. Young, J.W. Huh, et al. 2011. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob. Agents Chemother. 55: 5703-5709.
135. Barber, M.R., J.R. Aldridge Jr, R.G. Webster, et al. 2010. Association of RIG-I with innate immunity of ducks to influenza. Proc. Natl. Acad. Sci. U. S. A. 107: 5913-5918.
136. Olsen, S.J., K. Ungchusak, L. Sovann, et al. 2005. Family clustering of avian influenza A (H5N1). Emerg. Infect. Dis. 11: 1799-1801.
137. Boon, A.C., J. deBeauchamp, A. Hollmann, et al. 2009. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J. Virol. 83: 10417-10426.
138. Boon, A.C., D. Finkelstein, M. Zheng, et al. 2011. H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. MBio 2: e00171-11.
139. Swayne, D.E., & D.R. Kapczynski . 2008. "Vaccines, vaccination, and immunology for avian influenza viruses in poultry." In Avian Influenza. D.E. Swayne, Ed.: 407-451. Ames: Blackwell Publishing.